Filing Flows › Regenerative Medical Technology Group (RMTG) › Q1 2025
Regenerative Medical Technology Group (RMTG) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 20, 2025
Regenerative Medical Technology Group (RMTG) reported revenue of $1.4M for the first quarter 2025 (Q1 2025), +67% from a year earlier and -10% from the quarter before. Operating margin was 9.9%, net loss $760K (55.7% of revenue).
Regenerative Medical Technology Group, Q1 2025: revenue $1.4M (+67% year over year), operating margin 9.9%, net loss $760K, operating cash flow $57K. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.4M | -10% | +67% |
| Operating profit | $135K | -65% | — |
| Net earnings | −$760K | — | — |
| Operating cash flow | $57K | -85% | -47% |
What changed
Revenue was $1.4M in Q1 2025, up 67% year over year and down 10% from the previous quarter. Product Supplies was the largest line at 46% of revenue. Patient Procedures added $338K year over year (up 133%), 62% of the total change.
Gross margin was 69.2%, down 0.5 points from a year earlier. Operating profit was $135K, a 9.9% margin (up 22.8 points year over year). Operating expenses grew 20% against revenue growth of 67%. The fastest-growing cost line was General & admin (+54%). The quarter ended with a net loss of $760K, wider than the previous quarter's $638K loss. Net interest and other expense of $895K was the main reason.
Operating cash flow was $57K (down 47% year over year). Non-cash charges added back $52K of depreciation and amortization. Working capital and other items added $765K.
Questions
What was Regenerative Medical Technology Group's revenue in the first quarter 2025?
Regenerative Medical Technology Group (RMTG) reported revenue of $1.4M for the first quarter 2025 (Q1 2025), +67% from a year earlier and -10% from the quarter before.
Was Regenerative Medical Technology Group profitable in the first quarter 2025?
Operating profit was $135K (9.9% of revenue) and net loss $760K.
Source: Regenerative Medical Technology Group 10-Q on SEC EDGAR.